Bausch Health Companies
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The complaint accuses the defendants of making false and misleading statements regarding the spinoff of the Bausch + Lomb Corporation (B+L). These statements concerned the purported benefits of the spinoff for Bausch shareholders and the anticipated effects on Bausch after the spinoff. However, the complaint alleges that the real motive behind the spinoff was not to benefit shareholders but rather to undermine plaintiff lawsuits related to securities laws violations in 2016.
As a result of these allegedly deceptive statements, Bausch investors suffered significant financial losses. On August 6, 2020, when the spinoff was announced, Bausch’s stock closed at $20.13 per share. Subsequently, the stock reached a high of $34.38 per share before sharply declining to its current trading value of under $10 per share. The drop in the stock price reflects the damages incurred by investors who relied on the defendants’ misleading statements about the spinoff and its supposed benefits.
